ADH1B and ALDH Gene Variants and Lung Cancer Risk

Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Condition/Disease Adenocarcinoma Adenocarcinoma of Lung Carcinoma Disease Lung Adenocarcinoma Lung Cancer (Diagnosis) Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

About this study

This case-control study aims to investigate the association of ten genetic variants-nine SNPs across five ALDH family genes and one SNP in ADH1B (rs1229984)-with the risk of lung cancer and its major subtypes. The primary hypothesis is that the ALDH2 rs671 variant is associated with the risk of lung cancer and its major subtypes. The secondary hypothesis is that other ALDH variants-including rs2228093 and rs2073478 in ALDH1B1, rs1127717 and rs2276724 in ALDH1L1, rs3741172, rs17856219, and rs77341916 in ALDH3B2, and rs3765310 in ALDH5A1-are also associated with lung cancer risk. Demographic and lifestyle covariates such as age, gender, ethnicity, smoking status, alcohol consumption, educational level, and case-control status will be incorporated into the analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Incident lung cancer cases confirmed by pathology and healthy adult over age of 18 years.

Exclusion criteria

Individuals with incomplete data will not be included as study participants.

Treatment and study plan

Primary outcomes

Lung cancer status (case vs control)

Time frame: Not applicable (baseline status)

Lung cancer status determined by pathology-confirmed diagnosis at the time of case identification

Study contacts

Contact information is provided by the study sponsor or research team.

Tzu Yu Pan, PhD

CONTACT

[email protected]

886-3221806

Sponsors and collaborators

Lead sponsor

Kaohsiung Medical University

Other

Registry information

Official study title

Associations of ADH1B and ALDH Family Gene Polymorphisms With Lung Cancer Risk and Its Subtypes: Results From the Oncoarray Project of the International Lung Cancer Consortium

Acronym: ALDH

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Dec 9, 2025
Registry last updated: Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting